Skip to main content
SpringerLink
Log in

Anidulafungin

ECB, LY 303366, V-echinocandin, VEC, VER 002, VER-02

  • Adis R&D Profile
  • Published:
Drugs in R & D Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Table I
Table II

Notes

  1. This profile has been selected from R&D Insight™, a pharmaceutical intelligence database produced by Adis International Ltd.

References

  1. Versicor Inc. Versicor Announces Positive Phase II Results With Anidulafungin for Invasive Candidiasis/Candidemia. Media Release: 6 Jan 2003. Available from: URL: http://www.versicor.com

    Google Scholar 

  2. Ponsler GD, McMillian CL. Tissue pharmacokinetics of LY303366 and radioactivity in male F344 rats following a single intravenous bolus dose of 5 mg/kg. Pharmaceutical Research 14 (Suppl.): 71, Nov 1997

    Google Scholar 

  3. Ni L, Smith B, Hatcher B, et al. Pharmacokinetics of LY303366 in healthy and HIV-infected volunteers after single-dose oral administration. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy: 489, 24 Sep 1998

    Google Scholar 

  4. Thye D, Kilfoil T, White RJ, et al. Anidulafungin: pharmacokinetics in subjects with mild and moderate hepatic impairment. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy: 6 (plus poster), 22 Sep 2001

    Google Scholar 

  5. Lucas R, Desante K, Hatcher B. LY303366 single dose pharmacokinetics and safety in healthy male volunteers. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy: 108, 15 Sep 1996

    Google Scholar 

  6. Vicuron Pharmaceuticals Inc. Vicuron Submits New Drug Application for Anidulafungin to FDA. Media Release: 28 Apr 2003. Available from: URL: http://www.versicor.com

    Google Scholar 

  7. Thye D, Shepherd B, White RJ, et al. Anidulafungin: a phase 1 study to identify the maximum tolerated dose in healthy volunteers. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy: 6 (plus poster), 22 Sep 2001

    Google Scholar 

  8. Versicor Inc. Versicor Announces Positive Phase III Clinical Trial Results With Anidulafungin for Esophageal Candidiasis. Media Release: 17 Mar 2003. Available from: URL: http://www.versicor.com

    Google Scholar 

  9. Clemons KV, Sobel RA, Stevens DA. Toxicity of LY303366, an echinocandin antifungal, in mice pretreated with glucocorticoids. Antimicrobial Agents and Chemotherapy 44: 378–381, Feb 2000

    Article  PubMed  CAS  Google Scholar 

  10. White RJ, Thye D. Anidulafungin does not affect the metabolism of cyclosporin by human hepatic microsomes. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy: 6 (plus poster), 22 Sep 2001

    Google Scholar 

  11. Petraitiene R, Petraitis V, Groll AH. Antifungal activity of LY303366, a novel echinocandin B, in experimental disseminated candidiasis in rabbits. Antimicrobial Agents and Chemotherapy 43: 2148–2155, Sep 1999

    PubMed  CAS  Google Scholar 

  12. Zeckner D, Butler T, Boylan C. LY303366, activity in a rat mucocutaneous vaginal candidiasis model. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy: 252, 1994

    Google Scholar 

  13. Zeckner D, Butler T, Boylan C. LY303366, activity in a murine systemic candidiasis model. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy: 186, 1993

    Google Scholar 

  14. Zeckner D, Butler T, Boylan C. LY303366, activity against systemic aspergillosis and histoplasmosis in murine models. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy: 186, 1993

    Google Scholar 

  15. Verweij PE, Oakley KL, Morrissey J. Efficacy of LY303,366 against amphotericin B susceptible and resistant A. fumigatus infection in an immunocompromised murine model. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy: 158, 28 Sep 1997

    Google Scholar 

  16. Stevens DA. Drug interacvtion studies of a glucan synthase inhibitor (LY 303366) and a chitin synthase inhibitor (nikkomycin Z) for inhibiton and killing of fungal pathogens. Antimicrobial Agents and Chemotherapy 44: 2547–2548, Sep 2000

    Article  PubMed  CAS  Google Scholar 

  17. Current WL, Boylan CJ, Raab PP. Anti-pneumocystis activity of LY303366 and other echinocandin B analogs. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy: 186, 1993

    Google Scholar 

  18. Espinel-Ingroff A. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. Journal of Clinical Microbiology 36: 2950–2956, Oct 1998

    PubMed  CAS  Google Scholar 

  19. Pfaller MA, Marco F, Messer SA, et al. In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. Diagnostic Microbiology and Infectious Disease 30: 251–255, Apr 1998

    Article  PubMed  CAS  Google Scholar 

  20. Green LJ, Marder P, Mann LL. LY303366 exhibits rapid and potent fungicidal activity in flow cytometric assays of yeast viability. Antimicrobial Agents and Chemotherapy 43: 830–835, Apr 1999

    PubMed  CAS  Google Scholar 

  21. Espinel-Ingroff A, Turik MA, Arevalo P. The in vitro inhibitory and fungicidal activities of the new echinocandin LY303366 against Candida albicans. Ninety-Ninth General Meeting American Society for Microbiology: 138, 30 May 1999

    Google Scholar 

  22. Chávez M, Bernal S, Valverde A, et al. In-vitro activity of voriconazole (UK-109,496), LY303366 and other antifungal agents against oral Candida spp. isolates from HIV-infected patients. Journal of Antimicrobial Chemotherapy 44: 697–700, Nov 1999

    Article  PubMed  Google Scholar 

  23. Cuenca-Estrella M, Mellado E, Díaz-Guerra TM, et al. Susceptibility of fluconazole-resistant clinical isolates of Candida spp. to echinocandin LY303366, itraconazole and amphotericin B. Journal of Antimicrobial Chemotherapy 46: 475–477, Sep 2000

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Anidulafungin. Drugs R&D 4, 167–173 (2003). https://doi.org/10.2165/00126839-200304030-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-200304030-00005

Keywords

Search

Navigation